CYTK — Cytokinetics, Incorporated Share News
0.000.00%
Last trade - 00:00- $8.89bn
- $8.87bn
- $88.04m
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Cytokinetics Announces Additional Data From Acacia-Hcm Presented At The Hfsa Annual Scientific Meeting 2026
Brief: Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
Cytokinetics heart drug shows promise in trial, but analysts question modest benefits (updated)
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty
Cytokinetics rises after heart disease drug shows promise in late-stage study
Cytokinetics eyes expanded use of heart drug after promising late-stage data
Brief: Cytokinetics Plans To Submit Supplemental NDA To U.S. FDA For Aficamten In Q4 2026
Brief: Cytokinetics Announces Upcoming Presentations At The European Society Of Cardiology (Esc) Congress 2026
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Cytokinetics, Incorporated reports results for the quarter ended June 30 - Earnings Summary
Cytokinetics Q2 revenue falls as license revenue drops
Cytokinetics wins UK approval, NICE backing for heart disease drug
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Edgewise shares slip after heart-disease drug trial data disappoints investors
Brief: Cytokinetics Launches Myqorzo® (Aficamten) In European Union, With First Commercial Availability In Germany